Episode Summary
This episode presents an evidence-based analysis of the relationship between metabolic dysfunction and acne severity, exploring how insulin resistance, IGF-1 signaling, and systemic hormonal imbalances influence acne vulgaris pathogenesis. Moving beyond traditional dermatological mechanisms, the discussion examines metabolic and endocrine factors—including obesity, dyslipidemia, and polycystic ovary syndrome—that may significantly impact disease severity and treatment resistance in clinical practice.
Key Topics Discussed
- Insulin Resistance and Glucose Metabolism — mechanisms linking hyperinsulinemia to acne severity and sebaceous gland dysfunction
- IGF-1 and mTORC1 Signaling Pathways — central biological drivers of sebaceous activity, inflammation, and androgen bioavailability
- Obesity and Adipokine-Mediated Inflammation — role of chronic low-grade systemic inflammation in acne pathogenesis
- Dyslipidemia and Acne Association — heterogeneous relationships between lipid metabolism and disease severity
- Polycystic Ovary Syndrome and Hormonally-Driven Acne — endocrine dysregulation and clinical implications for women
- Metabolic Syndrome versus Individual Metabolic Components — clarifying inconsistent associations and clinical relevance
Key Takeaways
- While acne should not be classified as a metabolic disease, systemic metabolic and hormonal processes significantly influence disease severity and persistence
- The strongest evidence supports insulin resistance and IGF-1–mediated pathways as central mechanisms linking metabolic dysfunction to acne
- Early identification of metabolic risk factors in patients with severe, persistent, or treatment-resistant acne is clinically important
- An integrated, patient-centered dermatological approach incorporating assessment of metabolic and endocrine status improves clinical outcomes
- Further research is needed to clarify causality and develop targeted interventions for metabolically-influenced acne
About This Episode
Acne vulgaris remains one of the most prevalent dermatological conditions worldwide, affecting adolescents and adults across diverse populations. This episode addresses an important clinical gap by examining how metabolic dysfunction—increasingly prevalent in modern populations—intersects with dermatological disease. Understanding these mechanisms has significant implications for Georgian and global dermatological practice, particularly in managing complex, treatment-resistant cases and improving interdisciplinary patient care through collaboration between dermatologists, endocrinologists, and primary care physicians.
Acne vulgaris is one of the most common dermatological conditions worldwide, traditionally explained by androgen activity, follicular hyperkeratinization, sebaceous gland dysfunction, microbial imbalance, and inflammation. However, growing evidence suggests that systemic metabolic disturbances — including insulin resistance, IGF-1 signaling, obesity, dyslipidemia, and endocrine dysregulation — may significantly influence disease severity and persistence.
This episode explores how metabolic pathways interact with dermatological mechanisms, highlighting the role of insulin signaling, IGF-1 activation, and mTORC1 pathways in promoting sebaceous activity, inflammation, and androgen bioavailability.
The episode examines key clinical and public health considerations, including:
• The role of insulin resistance and glucose metabolism in acne severity
• IGF-1 and mTORC1 signaling as central biological drivers
• The impact of obesity, adipokines, and chronic low-grade inflammation
• Dyslipidemia and its heterogeneous association with acne
• The link between acne and endocrine disorders such as polycystic ovary syndrome
• The distinction between metabolic syndrome and its individual components
The findings indicate that while acne should not be classified as a metabolic disease, its severity may be influenced by systemic metabolic and hormonal processes. The strongest evidence supports insulin resistance and IGF-1–mediated pathways, while associations with metabolic syndrome remain inconsistent.
From a clinical perspective, this episode supports a more integrated, patient-centered dermatological approach, particularly in cases of severe, persistent, treatment-resistant, or hormonally driven acne.
This episode highlights the importance of interdisciplinary care, early identification of metabolic risk factors, and the need for further research to clarify causality and guide targeted interventions.
https://gmj.ge/index.php/pub/article/view/36
https://doi.org/10.5281/zenodo.19135373
Citation:
Inaishvili, M., & Glonti, S. (2026). Metabolic Dysfunction and Acne Severity: Mechanisms and Clinical Implications. The Georgian Medical Journal.
https://doi.org/10.5281/zenodo.19135373